ReviewSeminars in interventional radiology2013
Intra-arterial liver-directed therapies for neuroendocrine hepatic metastases.
Review in Seminars in interventional radiology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Comparison of transarterial bland and chemoembolization for neuroendocrine tumours: a systematic review and meta-analysis.Current oncology (Toronto, Ont.) · 2020Pooled it
- Treatment options for PNET liver metastases: a systematic review.World journal of surgical oncology · 2018Pooled it
- [Interventional therapeutic strategies for metastatic liver cancer].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026Review
- Current Status of Immunotherapy in Management of Small Bowel Neuroendocrine Tumors.Current oncology reports · 2024Review
- Non-cirrhotic hyperammonaemic encephalopathy secondary to metastatic pancreatic neuroendocrine tumour treated with peptide receptor radio nucleotide therapy and transarterial chemoembolisation.BMJ case reports · 2024Article
- Metastatic well differentiated serotonin-producing pancreatic neuroendocrine tumor with carcinoid heart disease: a case report.Journal of gastrointestinal oncology · 2023Article
- Endovascular image-guided sampling of tumor-draining veins provides an enriched source of oncological biomarkers.Frontiers in oncology · 2023Article
- The role of serotonin inhibition within the treatment of carcinoid syndrome.Endocrine oncology (Bristol, England) · 2023Review
- Article
- Carcinoid Heart Disease: How to Diagnose and Treat in 2020?Clinical Medicine Insights. Cardiology · 2020Review
- Prognostic value of baseline volumetric multiparametric MR imaging in neuroendocrine liver metastases treated with transarterial chemoembolization.European radiology · 2019Article
- Supportive therapy in gastroenteropancreatic neuroendocrine tumors: Often forgotten but important.Reviews in endocrine & metabolic disorders · 2018Review
- Hepatic intra-arterial therapies in metastatic neuroendocrine tumors: lessons from clinical practice.Endocrine · 2018Article
- Liver transarterial embolizations in metastatic neuroendocrine tumors.Reviews in endocrine & metabolic disorders · 2017Review
- Retrospective analysis of interventional treatment of hepatic metastasis from gastroenteropancreatic neuroendocrine tumors.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2017Article
- Intra-arterial therapy of neuroendocrine tumour liver metastases: comparing conventional TACE, drug-eluting beads TACE and yttrium-90 radioembolisation as treatment options using a propensity score analysis model.European radiology · 2017Observational
- Treatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversies.Expert opinion on pharmacotherapy · 2016Review
- Other non-surgical treatments for liver cancer.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation OncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Hepatic metastases, which are frequently seen in patients with neuroendocrine tumors (NETs), have a major adverse impact on the patient's quality of life and survival. Surgery is the treatment of choice for hepatic metastases but is possible in only a small percentage of patients. Systemic chemotherapy yields disappointing results. Somatostatin analogs are effective in controlling symptoms in many of these patients; however, the disease can become refractory to treatment. Transcatheter intra-arterial liver-directed therapies, such as hepatic artery embolization, chemoembolization, and radioembolization are frequently used in patients with NETs metastatic to the liver, especially in patients with refractory, unresectable, or recurrent disease. These treatments are effective in palliating the hormonal symptoms as well as achieving objective tumor responses. This review focuses on the technique, safety, and clinical efficacy of hepatic artery embolization, chemoembolization, and radioembolization in patients with metastatic NETs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.